PURPOSE: Long QT Syndrome, Marfan Syndrome, hypertrophic and dilated cardiomyopathy are caused by mutations in large, multi-exon genes that are principally expressed in cardiovascular tissues. Genetic testing for these disorders is labor-intensive and expensive. We sought to develop a more rapid, comprehensive, and cost-effective approach. METHODS: Paired whole blood samples were collected into tubes with or without an RNA-preserving solution, and harvested for whole blood RNA or leukocyte DNA, respectively. Large overlapping cDNA fragments from KCNQ1 and KCNH2 (Long QT Syndrome), MYBPC3 (hypertrophic and dilated cardiomyopathy), or FBN1 (Marfan Syndrome) were amplified from RNA and directly sequenced. Variants were confirmed in leukocyte DNA. RESULTS: All 4 transcripts were amplified and sequenced from whole blood mRNA. Six known and 2 novel mutations were first identified from RNA of 10 probands, and later confirmed in genomic DNA, at considerable savings in time and cost. In one patient with MFS, RNA sequencing directly identified a splicing mutation. Results from RNA and DNA were concordant for single nucleotide polymorphisms at the same loci. CONCLUSION: Taking advantage of new whole blood RNA stabilization methods, we have designed a cost-effective, comprehensive method for mutation detection that should significantly facilitate clinical genetic testing in four lethal cardiovascular disorders.
PURPOSE:Long QT Syndrome, Marfan Syndrome, hypertrophic and dilated cardiomyopathy are caused by mutations in large, multi-exon genes that are principally expressed in cardiovascular tissues. Genetic testing for these disorders is labor-intensive and expensive. We sought to develop a more rapid, comprehensive, and cost-effective approach. METHODS: Paired whole blood samples were collected into tubes with or without an RNA-preserving solution, and harvested for whole blood RNA or leukocyte DNA, respectively. Large overlapping cDNA fragments from KCNQ1 and KCNH2 (Long QT Syndrome), MYBPC3 (hypertrophic and dilated cardiomyopathy), or FBN1 (Marfan Syndrome) were amplified from RNA and directly sequenced. Variants were confirmed in leukocyte DNA. RESULTS: All 4 transcripts were amplified and sequenced from whole blood mRNA. Six known and 2 novel mutations were first identified from RNA of 10 probands, and later confirmed in genomic DNA, at considerable savings in time and cost. In one patient with MFS, RNA sequencing directly identified a splicing mutation. Results from RNA and DNA were concordant for single nucleotide polymorphisms at the same loci. CONCLUSION: Taking advantage of new whole blood RNA stabilization methods, we have designed a cost-effective, comprehensive method for mutation detection that should significantly facilitate clinical genetic testing in four lethal cardiovascular disorders.
Authors: Mary E Winn; Matthew A Zapala; Iiris Hovatta; Victoria B Risbrough; Elizabeth Lillie; Nicholas J Schork Journal: Mamm Genome Date: 2010-05-16 Impact factor: 2.957
Authors: Qiuming Gong; Li Zhang; Arthur J Moss; G Michael Vincent; Michael J Ackerman; Jeffrey C Robinson; Melanie A Jones; David J Tester; Zhengfeng Zhou Journal: J Mol Cell Cardiol Date: 2008-01-17 Impact factor: 5.000
Authors: Dong-Chuan Guo; Prateek Gupta; Van Tran-Fadulu; Tera V Guidry; Magalie S Leduc; Frederick V Schaefer; Dianna M Milewicz Journal: J Hum Genet Date: 2008-09-17 Impact factor: 3.172
Authors: Elisa Molinari; Eva Decker; Holly Mabillard; James Tellez; Shalabh Srivastava; Shreya Raman; Katrina Wood; Caroline Kempf; Sumaya Alkanderi; Simon A Ramsbottom; Colin G Miles; Colin A Johnson; Friedhelm Hildebrandt; Carsten Bergmann; John A Sayer Journal: Eur J Hum Genet Date: 2018-07-12 Impact factor: 4.246
Authors: Lauren C Tindale; Nina Thiessen; Stephen Leach; Angela R Brooks-Wilson Journal: J Gerontol A Biol Sci Med Sci Date: 2020-05-22 Impact factor: 6.053